Tedizolid (856866-72-3) and intermediates, NMR, HPLC 99%+, LCMS, COA and ROS is ok, Pls kindly check:
1.
Tedizolid (856866-72-3), HPLC, NMR, LCMS, COA，ROS is ok, stock more than 5kg. Assay 99% in GMP plant, C-GMP standard.
Name: Tedizolid
CAS NO.: 856866-72-3
Chemical Formula: C17H15FN6O3
Exact Mass: 370.119
Molecular Weight: 370.3444
Elemental Analysis: C, 55.13; H, 4.08; F, 5.13; N, 22.69; O, 12.96
Description: Tedizolid, also known as TR-700, DA-7157, Torezolid, is an oxazolidinone-class antibiotic. Tedizolid has been approved by FDA on June 20, 2014, for the treatment of acute bacterial Skin and skin structure infections (ABSSSI).
2.
Tedizolid (856866-72-3) intermediates:
Tedizolid intermediate 1220910-89-3, we have more than 25kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 1218791-13-9, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 1056039-83-8, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 380380-64-3, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 380380-63-2, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 380380-60-9, we have more than 25kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 504438-22-6, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 444335-16-4, we have more than 25kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 510729-01-8, we have more than 25kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 16681-80-4, we have more than 25kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 402717-52-6, we have more than 5kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Tedizolid intermediate 20059-87-4, we have more than 3kg in stock, assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Related CAS: 856866-72-3
Synonym: TR-700; TR 700; TR700; DA-7157; DA7157; DA 7157; Tedizolid; Torezolid. trade name Sivextro
IUPAC/Chemical Name: (5R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
InChi Key: XFALPSLJIHVRKE-GFCCVEGCSA-N
InChi Code: InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
SMILES Code: O=C1O[C@@H](CO)CN1C2=CC=C(C3=CC=C(C4=NN(C)N=N4)N=C3)C(F)=C2
TECHNICAL DATA
Appearance: Solid powder
Purity: >98%
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term
Harmonized System Code: 293490
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
REFERENCES
1: Ortiz A, Fang E, Prokocimer P, Flanagan S, Zhu X, Cabré-Márquez JF, Tanaka T, Passarell J, Fiedler-Kelly J, Nannini E. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. Braz J Infect Dis. 2016 Feb 6. pii: S1413-8670(16)30024-1. doi: 10.1016/j.bjid.2015.12.007. [Epub ahead of print] PubMed PMID: 26859064.
2: Yu HC, Pan CW, Xie QP, Zheng Y, Hu YZ, Lin YM. Simultaneous determination of tedizolid and linezolid in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Feb 1;1011:94-8. doi: 10.1016/j.jchromb.2015.12.056. Epub 2016 Jan 2. PubMed PMID: 26773886.
3: Michalska K, Gruba E, Cielecka-Piontek J, Bednarek E. Chiral separation of tedizolid using charge single isomer derivatives of cyclodextrins by capillary electrokinetic chromatography. J Pharm Biomed Anal. 2016 Feb 20;120:402-12. doi: 10.1016/j.jpba.2015.11.022. Epub 2015 Dec 24. PubMed PMID: 26724911.
4: Fala L. Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin-Structure Infections. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):111-5. PubMed PMID: 26629275; PubMed Central PMCID: PMC4665048.
5: Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16. PubMed PMID: 26476277.
6: Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015 Dec;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12. PubMed PMID: 26457865.
7: Kennedy G, Osborn J, Flanagan S, Alsayed N, Bertolami S. Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration. Drugs R D. 2015 Dec;15(4):329-33. doi: 10.1007/s40268-015-0108-6. PubMed PMID: 26416654; PubMed Central PMCID: PMC4662946.
8: Chen KH, Huang YT, Liao CH, Sheng WH, Hsueh PR. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia. Antimicrob Agents Chemother. 2015 Oct;59(10):6262-5. doi: 10.1128/AAC.00390-15. Epub 2015 Jul 27. PubMed PMID: 26248355; PubMed Central PMCID: PMC4576035.
9: Hui Y, Xiaoju L. Tedizolid for treatment of acute bacterial skin and skin structure infections. Expert Rev Anti Infect Ther. 2015;13(9):1051-60. doi: 10.1586/14787210.2015.1073107. Epub 2015 Jul 27. PubMed PMID: 26211946.
10: Lee Y, Hong SK, Choi S, Im W, Yong D, Lee K. In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study. Ann Lab Med. 2015 Sep;35(5):523-30. doi: 10.3343/alm.2015.35.5.523. PubMed PMID: 26206690; PubMed Central PMCID: PMC4510506.
11: Chahine EB, Sucher AJ, Knutsen SD. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections. Consult Pharm. 2015 Jul;30(7):386-94. doi: 10.4140/TCP.n.2015.386. PubMed PMID: 26173190.
12: Lewis SJ, Switaj LA, Mueller BA. Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy. Blood Purif. 2015;40(1):66-71. doi: 10.1159/000430904. Epub 2015 Jun 27. PubMed PMID: 26138225.
13: Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Epub 2015 Jun 23. PubMed PMID: 26105167.
14: Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections - focus on tedizolid. Ther Clin Risk Manag. 2015 May 22;11:857-62. doi: 10.2147/TCRM.S64553. eCollection 2015. Review. PubMed PMID: 26045667; PubMed Central PMCID: PMC4447168.
15: Hall RG 2nd, Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Infect Drug Resist. 2015 Apr 22;8:75-82. doi: 10.2147/IDR.S56691. eCollection 2015. Review. PubMed PMID: 25960671; PubMed Central PMCID: PMC4411017.
16: Prokocimer P, Corey GR, Das AF, Moran GJ. A closer inspection of tedizolid - authors' reply. Lancet Infect Dis. 2015 Apr;15(4):375. doi: 10.1016/S1473-3099(15)70103-9. PubMed PMID: 25809888.
17: Taylor J. A closer inspection of tedizolid. Lancet Infect Dis. 2015 Apr;15(4):374. doi: 10.1016/S1473-3099(15)70055-1. PubMed PMID: 25809887.
18: Drekonja DM. A closer inspection of tedizolid. Lancet Infect Dis. 2015 Apr;15(4):374. doi: 10.1016/S1473-3099(15)70056-3. PubMed PMID: 25809886.
19: Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23. PubMed PMID: 25801564; PubMed Central PMCID: PMC4432129.
